Wearable heart monitor measures variability

It’s no secret wearables are in fashion these days. In the first three months of 2016 alone, more than a quarter billion dollars in venture capital was invested in the booming market.

Now, one Canadian hospital is hoping to use digital monitoring to improve care in its ICU. Rockyview General Hospital in Calgary, Alberta, is using biometric devices from biotricty Inc. to determine the effectiveness of monitoring heart rate variability (HRV) to predict the onset of illness.

The devices aim to improve data available to healthcare providers, since many current monitors only sample heart rate at an interval, instead of measuring the time between each single beat.

“AHS will utilize biotricity’s medical grade, high-resolution ECG and wireless communication capabilities as a perioperative wellness and recovery monitor which we believe will improve outcomes and reduce complications,” said David Liepert, MD, a University of Calgary professor and Rockyview anesthesiologist who is leading the study.

The researchers will aim to use biotricity’s monitors to follow a patient from pre-surgery, through the procedure, and throughout recovery. The research team believes the monitor could result in a reduction of post-surgery complications such as wound infections and blood clots.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.